KR20040048935A - 인간 모노클로날 항체를 이용한 비형 간염 바이러스감염의 치료 - Google Patents

인간 모노클로날 항체를 이용한 비형 간염 바이러스감염의 치료 Download PDF

Info

Publication number
KR20040048935A
KR20040048935A KR10-2004-7004987A KR20047004987A KR20040048935A KR 20040048935 A KR20040048935 A KR 20040048935A KR 20047004987 A KR20047004987 A KR 20047004987A KR 20040048935 A KR20040048935 A KR 20040048935A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
hbv
monoclonal antibody
human monoclonal
hepatitis
Prior art date
Application number
KR10-2004-7004987A
Other languages
English (en)
Korean (ko)
Inventor
슬로모 다간
라첼 에렌
Original Assignee
엑스티엘 바이오파마수티칼즈 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스티엘 바이오파마수티칼즈 엘티디. filed Critical 엑스티엘 바이오파마수티칼즈 엘티디.
Publication of KR20040048935A publication Critical patent/KR20040048935A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2004-7004987A 2001-10-04 2001-10-04 인간 모노클로날 항체를 이용한 비형 간염 바이러스감염의 치료 KR20040048935A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2001/000927 WO2003028722A1 (fr) 2001-10-04 2001-10-04 Traitement des infections par le virus de l'hepatite b avec des anticorps monoclonaux humains

Publications (1)

Publication Number Publication Date
KR20040048935A true KR20040048935A (ko) 2004-06-10

Family

ID=11043099

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7004987A KR20040048935A (ko) 2001-10-04 2001-10-04 인간 모노클로날 항체를 이용한 비형 간염 바이러스감염의 치료

Country Status (7)

Country Link
EP (1) EP1432418A1 (fr)
JP (1) JP2005505582A (fr)
KR (1) KR20040048935A (fr)
CN (1) CN1558763A (fr)
CA (1) CA2462427A1 (fr)
IL (1) IL161138A0 (fr)
WO (1) WO2003028722A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017018739A1 (fr) * 2015-07-24 2017-02-02 Mogam Institute For Biomedical Research Composition pharmaceutique permettant d'empêcher la formation d'adnccc du virus de l'hépatite b

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9292111B2 (en) 1998-01-26 2016-03-22 Apple Inc. Gesturing with a multipoint sensing device
US8479122B2 (en) 2004-07-30 2013-07-02 Apple Inc. Gestures for touch sensitive input devices
CA2594922A1 (fr) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Anticorps monoclonaux se liant avec le virus de l'hepatite b ou le neutralisant
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
KR20090056537A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
CN102757492A (zh) * 2011-04-26 2012-10-31 中国人民解放军第二军医大学 全人乙肝表面蛋白单克隆抗体及其在制备预防hbv感染药物中的用途
CN105001325A (zh) * 2015-07-31 2015-10-28 北京泰诺迪生物科技有限公司 一种全人源抗乙肝病毒中和抗体及其制备方法与应用
WO2017114812A1 (fr) * 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Traitement combiné avec un inhibiteur de hbsag et un interféron
EP3519443A4 (fr) * 2016-09-30 2020-06-10 Baylor College of Medicine Thérapie par récepteurs d'antigène chimériques présentant une cytotoxicité réduite pour maladie virale

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0893124A1 (fr) * 1997-07-24 1999-01-27 Roche Diagnostics GmbH Préparations pharmaceutiques combinées comprenant des anticorps monoclonaux humains pour le traitement de l'hépatite B et une substance virostatique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017018739A1 (fr) * 2015-07-24 2017-02-02 Mogam Institute For Biomedical Research Composition pharmaceutique permettant d'empêcher la formation d'adnccc du virus de l'hépatite b

Also Published As

Publication number Publication date
CA2462427A1 (fr) 2003-04-10
JP2005505582A (ja) 2005-02-24
EP1432418A1 (fr) 2004-06-30
IL161138A0 (en) 2004-08-31
CN1558763A (zh) 2004-12-29
WO2003028722A1 (fr) 2003-04-10

Similar Documents

Publication Publication Date Title
Bienzle et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease
Liang et al. Present and future therapies of hepatitis B: from discovery to cure
RUSTGI et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome
Galun et al. Clinical evaluation (phase I) of a combination of two human monoclonal antibodies to HBV: safety and antiviral properties
Eren et al. Preclinical evaluation of two human anti–hepatitis B virus (HBV) monoclonal antibodies in the HBV‐trimera mouse model and in HBV chronic carrier chimpanzees
Lo et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B
US20170260257A1 (en) Antibody composition for prevention or treatment of mutant hepatitis b virus infection
Nevens et al. Treatment of decompensated viral hepatitis B‐induced cirrhosis with low doses of interferon alpha
Xu et al. Vaccination with recombinant HBsAg–HBIG complex in healthy adults
Goyal et al. Hepatitis B vaccination in acute lymphoblastic leukemia
KR20040048935A (ko) 인간 모노클로날 항체를 이용한 비형 간염 바이러스감염의 치료
CN101878037A (zh) 能够中和乙型肝炎病毒的人抗体在预防或治疗乙型肝炎病毒感染中的用途
Cotonat et al. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients
US20050260195A1 (en) Treatment of hepatitis B virus infection with human monoclonal antibodies
Burm et al. A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
Bosch et al. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C
Rokicka‐Milewska et al. Active immunization of children with leukemias and lymphomas against infection by hepatitis B virus
Heijtink et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre‐treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes
Gaeta et al. Epidemiology of chronic viral hepatitis in the Mediterranean area: present status and trends
AU2002210869A1 (en) Treatment of hepatitis B virus infection with human monoclonal antibodies
Januszkiewicz et al. Hepatitis B and C virus infection in Polish children with malignancies
Fagan et al. Serological responses to HBV infection.
US5529776A (en) Anti-HIV-1 neutralizing antibodies
Bogusławska-Jaworska et al. Passive and active anti-hepatitis B immunization of children with hematological malignancies
Petruff et al. Hepatitis vaccines

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E601 Decision to refuse application